CASI Pharmaceuticals Shareholders’ Equity Growth & History (CASIF)

CASI Pharmaceuticals's shareholders’ equity was −$37.3M for fiscal 2025.

View full CASI Pharmaceuticals company overview

CASI Pharmaceuticals annual shareholders’ equity history

CASI Pharmaceuticals annual shareholders’ equity

Fiscal yearPeriod endedShareholders’ equityChangeGrowth
20252025-12-31−$37.3M−$39.1M
20242024-12-31$1.9M−$22.3M−92.34%
20232023-12-31$24.2M−$20.4M−45.79%
20222022-12-31$44.6M−$39.9M−47.25%
20212021-12-31$84.5M$3.0M+3.63%
20202020-12-31$81.5M

CASI Pharmaceuticals shareholders’ equity trends

Over the last five fiscal years, CASI Pharmaceuticals's shareholders’ equity decreased from $81.5M to −$37.3M, a change of −$118.8M. The latest reported quarter, Q2 2026, shows −$58.3M.

About the metric

What shareholders’ equity means

Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.

Calculation and source

SEC-reported shareholders’ equity

TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review CASI Pharmaceuticals source filings ↗

Community posts

It’s quiet here.

No posts about CASIF yet. Start the conversation.

Write the first post